中文
R&D
Pipeline
| Candidate (Dosage form) | Target（Modality） | Indication (Dosage/Administration) | Discovery - | Preclinical - | Phase I - | Phase II - | Phase III - | NDA - | |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial Infections | Rifasutenizol* (Oral) | RNA polymerase and nitroreductase | H. pylori infection (capsule) | NMPA | |||||
| H. pylori infection (tablet) | FDA | ||||||||
| Bacterial vaginosis | NMPA | ||||||||
| C. difficile infection | NMPA | ||||||||
| TNBi-1 | Confidential (Narrow spectrum novel small molecule drug) | H. pylori infection | |||||||
| Rifaquizinone* (Injectable) | RNA polymerase, DNA gyrase, and topoisomerase IV | PJI (IV) | NMPA
| ||||||
FDA
| |||||||||
| PJI (IA) | NMPA | ||||||||
| ABSSSI (IV) | NMPA
| ||||||||
FDA
| |||||||||
| LVADI (IV) | FDA
| ||||||||
| CRBSI (IV) | FDA
| ||||||||
| TNP-2092 (Topical) | RNA polymerase, DNA gyrase, and topoisomerase IV | DFI | NMPA | ||||||
| TNBi-2 | Confidential (Multi-targeting molecule drug) | NTM-PD | |||||||
| Bacterial Metabolism | TNP-2092* （Oral） | RNA polymerase, DNA gyrase and topoisomerase IV | HE | NMPA | |||||
| IBS-D | NMPA | ||||||||
| TNBm-1 | Confidential (Bifunctional small molecule drug) | Metabolic diseases |
Notes:
* Core ProductTechnology
TenNor Therapeutics has a unique multi-targeting drug conjugate technology platform-a fully integrated R&D engine that drives innovation. All of TenNor’s drug candidates are conjugated molecules with multi-targeting mechanism of action, developed through this platform. It spans the full spectrum of drug design, synthesis, and evaluation, specifically focused on candidates targeting bacterial infections and bacterial metabolism. The primary goal in developing this platform is to address the critical challenges in antibacterial drug development, namely, antimicrobial resistance and antimicrobial tolerance. With this platform, TenNor Therapeutics carefully selects potential targets, design and synthesize conjugate molecules, and iteratively fine-tune the molecular structure based on evaluation results.
Medical Needs
Antimicrobial agents are the cornerstone of modern medicine, saving countless lives and making many common surgeries possible. However, the problem of antimicrobial resistance is becoming more and more serious and has become a major challenge to the prevention and treatment of bacterial infections. At present, some important pathogenic bacteria have developed resistance to almost all existing antibacterial drugs, rendering the clinical treatment extremely difficult.
H. pylori Infection
Medical Device Associated Bacterial Biofilm Infection
Liver Cirrhosis Hepatic Encephalopathy
Partnering
TenNor Therapeutics proactively embraces external partnering opportunities in Chinese and overseas markets.
We warmly welcome any inquiries from domestic and overseas partners who are in great strategic/product synergies with us.
TNP-2198 口服剂
治疗厌氧菌和微需氧菌感染，包括幽门螺杆菌感染、细菌性阴道病和艰难梭菌感染
微需氧菌和厌氧菌感染与很多常见和重大疾病相关，包括幽门螺杆菌感染、细菌性阴道病和艰难梭菌感染等，目前由于耐药问题严重，临床上存在重大未满足的需求。TNP-2198是一个独特的多靶点偶联分子，具有多靶点协同作用机制，对耐药菌株具有较强的杀菌活性并具有较低的耐药的频率，在治疗幽门螺杆菌感染、细菌性阴道病和艰难梭菌感染等方面具有广泛的应用前景。丹诺医药已经在健康志愿者中完成了TNP-2198的2项I期临床试验和1项临床药理试验，并在幽门螺杆菌感染者中完成了TNP-2198胶囊的2项II期临床试验。目前，正开展TNP-2198治疗幽门螺杆菌感染的III期临床试验，为在胃癌高发人群中采取幽门螺杆菌筛查-根除策略，预防胃癌，提供一个有效的工具。TNP-2198是国家“重大新药创制”科技重大专项支持项目并获得美国FDA的QIDP资格认定。